BLACKROCK INCOME AND GROWTH INVESTMENT TRUST PLC
All information is at 31 January 2015 and unaudited.
Performance at month end with net income reinvested
One Three One Since Three Five
month months year 1 April years years
2012
Sterling:
Share price 4.7% 10.0% 16.3% 52.5% 61.1% 68.6%
Net asset value 4.4% 8.8% 15.8% 40.8% 45.0% 64.3%
FTSE All-Share Total Return 2.6% 3.9% 7.1% 32.8% 37.1% 61.5%
Source: BlackRock
BlackRock took over the investment management of the Company with effect from 1 April 2012.
At month end
Sterling:
Net asset value - capital only: 181.46p
Net asset value - cum income*: 185.78p
Share price: 184.00
Total assets (including income): £51.2m
Discount to cum-income NAV: 1.0%
Net Gearing: nil
Net yield**: 3.0%
Ordinary shares in issue***: 26,479,268
Gearing range (as a % of net assets) 0-20%
Ongoing charges****: 1.2%
* includes net revenue of 4.32 pence per share
** based on an interim dividend of 2.20p per share for the financial year ended
31 October 2014 and a final dividend of 3.50p per share in respect of the year
ended 31 October 2013.
*** excludes 6,454,664 shares held in treasury
**** Calculated as a percentage of average net assets and using expenses,
excluding performance fees and interest costs for the year ended 31 October
2014.
Benchmark
Sector Analysis Total assets (%)
Support Services 11.2
Life Insurance 9.9
Tobacco 9.9
Travel & Leisure 9.0
Pharmaceuticals & Biotechnology 8.5
Banks 7.6
Oil & Gas Producers 6.7
Media 5.0
General Retailers 4.1
Mining 3.8
Household Goods & Home Construction 3.4
Non-Life Insurance 3.4
Food Producers 2.8
Electronic & Electrical Equipment 2.6
Financial Services 2.1
Beverages 2.1
Personal Goods 2.1
General Industrials 1.4
Net Current Assets 4.4
Total 100.0
Ten Largest Equity Investments
Company Total assets(%)
British American Tobacco 5.3
HSBC 4.9
Imperial Tobacco 4.6
AstraZeneca 4.5
Reed Elsevier 3.9
Prudential 3.9
Rio Tinto 3.8
Friends Life 3.5
Wolseley 3.5
Royal Dutch Shell `B' 3.4
Commenting on the markets, Adam Avigdori & Mark Wharrier representing the
Investment Manager noted:
Markets
UK equities rose in January, extending the rebound that began in October.
Expectations for positive European Central Bank (ECB) action increased after
the Swiss National Bank announced the removal of the cap on the Swiss Franc
against the Euro. The ECB announcement of Quantitative Easing (QE) to purchase
€60bn per month of eurozone government and asset backed securities had a
positive effect on equity markets. Weaker than expected UK fourth quarter GDP
led to expectations of UK interest rates being lower for longer. The market was
led higher by European focused companies and traditional `bond proxies' such as
utilities and companies that have delivered consistent, earnings growth. The search
by investors for yield intensified in light of ECB QE further pushing down bond yields.
The Company returned 4.4%* in January, outperforming the FTSE All-Share Index
total return of 2.6%.
Portfolio Performance
A broad range of companies contributed positively to performance. Imperial
Tobacco, British American Tobacco and Reed Elsevier were all strong performers
during the month. Next, announced a rise in expected full year profits following
strong sales in the run up to Christmas. Next also benefited from taking a disciplined
approach to the "Black Friday" price cutting promotions and announced their fourth
special dividend for the year. Our holding in Essentra also benefitted as the shares
rebounded on improving sentiment towards the European economy following the ECB's
announcement of QE. Essentra currently earns half its revenues from European
customers. Our holding in Friends Life continued to rally as the synergies from
the combination with Aviva became apparent.
One of the biggest detractors to relative performance over the month came from
not owning Tesco. The shares, which were one of the weakest performers in 2014,
rebounded strongly on hopes that management change can restore value. While the
new management team is certainly a step forward, the turnaround is likely to be
protracted given the weak balance sheet and the structural changes in the UK
supermarket industry, namely the growth of the German discounters and internet
shopping. Other detractors over the month were Dixons Carphone, Rio Tinto and
Berkeley Group.
Activity over the month included new purchases in Lloyds Banking Group and
Stagecoach with additions to our holdings in Hays, Imperial Tobacco, Burberry
and Next. We reduced our positions in Royal Dutch Shell and British American
Tobacco and sold out of Marks & Spencer.
Outlook
Eurozone economic activity remains subdued despite an increasingly supportive
policy response from the ECB, whilst in the US the ending of QE is contributing
to uncertainty. We continue to focus more on the specific drivers of individual
companies and the ability to determine their future rather than relying on a
specific macro outcome. Given the outlook for both economic growth and interest
rates remains uncertain, we seek those companies that can drive returns through
self-help and have a clear strategy to deploy the cashflow they generate. The
portfolio is primarily invested in high free cash flow companies that can
sustain cash generation and pay a growing dividend yield, but also has exposure
to companies with sustainable growth franchises and turnaround situations.
* NAV - Inc. performance.
11 February 2014
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.